37 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
19 May 21
Regulation FD Disclosure
5:00pm
other ovarian cancer clinical trials. The need for new treatment options for this community drives our efforts to potentially bring STRO-002
8-K
EX-99.1
STRO
Sutro Biopharma Inc
10 Aug 23
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
significant interest of luvelta within the medical community, providing momentum for patient enrollment into REFRaME across our global sites," said Bill
8-K
EX-99.1
STRO
Sutro Biopharma Inc
15 Jun 20
Regulation FD Disclosure
7:21am
Potentially Available in Community Oncology Centers CC-99712 was discovered and developed using Sutro’s XpressCF® Source: Bristol-Myers Squibb ASH 2019
PRE 14A
t1jlo7dx
14 Apr 23
Preliminary proxy
4:05pm
DEF 14A
0f6s61n
26 Apr 19
Definitive proxy
12:00am
10-Q
qophnbc ss8u5
14 Nov 18
Quarterly report
12:00am